Armeni Patrizio, Polat Irem, De Rossi Leonardo Maria, Diaferia Lorenzo, Meregalli Severino, Gatti Anna
LIFT Lab, CERGAS GHNP Division, SDA Bocconi School of Management, Milano, Italy.
LIFT Lab, CERGAS GHNP Division, and DEVO Lab, Claudio Demattè Research Division, SDA Bocconi School of Management, Milano, Italy.
Digit Health. 2024 Sep 12;10:20552076241277441. doi: 10.1177/20552076241277441. eCollection 2024 Jan-Dec.
Digital therapeutics (DTx), a burgeoning subset of digital health solutions, has garnered considerable attention in recent times. These cutting-edge therapeutic interventions employ diverse technologies, powered by software algorithms, to treat, manage, and prevent a wide array of diseases and disorders. Although DTx shows significant promise as an integral component of medical care, its widespread integration is still in the preliminary stages. This limited adoption can be largely attributed to the scarcity of comprehensive research that delves into DTx's scope, including its technological underpinnings, potential application areas, and challenges-namely, regulatory hurdles and modest physician uptake. This review aims to bridge this knowledge gap by offering an in-depth overview of DTx products' value to both patients and clinicians. It evaluates the current state of maturity of DTx applications driven by digital technologies and investigates the obstacles that developers and regulators encounter in the market introduction phase.
数字疗法（DTx）是数字健康解决方案中一个新兴的子集，近年来受到了广泛关注。这些前沿的治疗干预措施采用由软件算法驱动的多种技术，来治疗、管理和预防各种各样的疾病和紊乱。尽管数字疗法作为医疗保健的一个组成部分显示出巨大的潜力，但其广泛整合仍处于初步阶段。这种有限的采用在很大程度上可归因于深入研究数字疗法范围的全面研究稀缺，包括其技术基础、潜在应用领域以及挑战——即监管障碍和医生接受度不高。本综述旨在通过深入概述数字疗法产品对患者和临床医生的价值来弥合这一知识差距。它评估了由数字技术驱动的数字疗法应用的当前成熟状态，并调查了开发者和监管机构在市场引入阶段遇到的障碍。
